My PCR
Create Account
Logo PCR

INVICTUS - Rivaroxaban versus VKA for rheumatic atrial fibrillation

Reported from ESC Congress 2022

Aaysha Cader interviews Ganesan Karthikeyan who presented the results of INVICTUS during the ESC Congress 2022 in Barcelona: Among patients with rheumatic heart disease–associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding.

 

Latest news from ESC Congress 2022

Authors

Aaysha Cader
Aaysha Cader
@aayshacader

Cardiology SpR

Kettering General Hospital NHS Foundation Trust - Kettering, United Kingdom

Ganesan Karthikeyan
Ganesan Karthikeyan
@@drkarthik2010

Interventional cardiologist / Cardiologist

All India Institute Of Medical Sciences - New Delhi, India

Join the discussion

2 comments

  • Sajal Banerjee 29 Aug 2022

    Warm Congratulations to both the Cardiologists- presenter of INVICTUS Trial Prof.Ganesan Karthikeyan of AIMS &one of the investigator of the trial as well as interviewer Dr.AayshaCader of ICH&RI,Bangladesh.INVICTUS is an exceptional great study.I feel really proud for Dr.Aaysha Cader.Best wishes to everyone. Prof.Sajal Banerjee,BSMMU,Dhaka, Bangladesh.

  • Sajal Banerjee 30 Aug 2022

    Warm Congratulations to all Investigators & Participants for the outstanding study INVICTUS, presented in ESC2022 Congress particularly to the presenter Prof.Ganesan Karthikeyan of AIMS,Delhi & one of the investigator as well as interviewer Dr.Aaysha Cader of ICH&RI,Dhaka,Bangladesh.Feeling specially proud for Dr.Aaysha Cader.Best wishes to everyone.